|Day Low/High||2.47 / 2.57|
|52 Wk Low/High||2.25 / 3.89|
The company reported quarterly earnings that were ahead of Wall Street's estimates.
The companies will work to develop and commercialize three phase II antibody products.
Longs have no cause to sell as the company absorbs its breakout gains. Plus the Nasdaq and more.
Its recent climb makes it seem like a good short, but history says otherwise. Plus, TiVo and more.
The Arms Index's 10-day moving average is quite oversold, kindling prospects of an imminent rally.
Signs of life are returning to these stocks. Here are three that could outperform the rest.
The company will not seek fast-track regulatory approval for its colitis treatment.
We may be a little overdone to the upside in the short term, but the long-term picture is encouraging.
The biotech company drops plans to pursue antibody as treatment for colitis.
Earnings news returns to the fore as rate fears get factored in.
Keep abreast of events that will bring volatility and trading opportunities back to the market.
You can't rule out the possibility that a deal is inked, but for which drugs and on what terms?
Which way will it break? In a special section, Alan gives his trading outlook for December.
Excluding one-time items, the company's loss topped estimates.
Some signals indicate Genentech may want to pull out of the licensing deal.
The selling was widespread on a day the overall market also slumped.
Its Avastin proves effective vs. colon cancer in a Phase III trial.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.